Dashboard
Discussions
Watchlists
Collections
Tools
More
Events
SIGN UP
SIGN IN
Sign in with Google. Opens in new tab
ENTITY
Medy Tox Inc (086900 KS)
Watchlist
56
Analysis
Health Care
•
South Korea
Medy-Tox Inc. is a biopharmaceutical company. The Company researches, develops and manufactures biopharmaceutical products using clostridium botulinum which is a microorganism toxin.
more
Watchlist
All
Insights
Broker
Sponsored
Syndicated
Podcast
Buy side
Refresh
Focused
Suggested
bearish
•
Thematic (Sector/Industry)
•
28 Mar 2019 13:42
Smartkarma’s Week That Was in JP/KR: Semiconductor Warnings, Exit of Chairman Cho, & 청년수당
In the past week, there were earnings warnings from three major players in the global semiconductor sector, including Samsung Electronics (005930...
Douglas Kim
Follow
679 Views
Share
bearish
•
Daewoong Pharmaceutical Co
•
27 Mar 2019 23:36
Daewoong: Entering "Botox World"
Daewoong Pharmaceutical Co (069620 KS) has traded up over the past year in anticipation of the launch of its botulinum toxin product Jeuveau in the...
Kemp Dolliver, CFA
596 Views
Share
bullish
•
Cross Asset Strategy
•
26 Nov 2018 21:23
EM Health Care: Late Cycle Rotation
Emerging Market Health Care allocations sit towards the lower end of their 7-year range. Current levels are off their 2015 highs by a margin, with...
Steven Holden
Follow
416 Views
Share
bullish
•
Thematic (Sector/Industry)
•
17 Jan 2018 07:06
KRX 300 - Selection Process Summary & Current Mood
Feb 5 is our big day. On Feb 5 the KRX will announce more details about this highly anticipated and much awaited new KOSPI+KOSDAQ integrated...
Sanghyun Park
Follow
616 Views
Share
bullish
•
Thematic (Sector/Industry)
•
25 Nov 2017 13:53
Summary of KOSDAQ 150 December Reshuffle & Rebalancing
It was officially announced that a total of 13 stocks would be newly added to KOSDAQ 150 in the upcoming periodical reshuffle, whereas the same...
Sanghyun Park
Follow
610 Views
Share
First
Previous
3
4
5
6
7
8
9
Next
Last
For Institutional Investors and Financial Services
For Corporate IR and Strategy
For Private Wealth Intermediaries
Pricing
Who We Are
Careers
FAQs
Research Provider Solutions
Syndicate your Publications
Compliance
Terms of Use
Privacy Policy
Press Kit
RSS Feeds
Request a Free Trial
Avail a Transition Account
Guest Posts on Smartkarma
Other Enquiries
Join TL;DR Community
Free Weekly Newsletters
Copyright © 2022 Smartkarma Innovations Pte Ltd. All Rights Reserved. v3.53.10
x